Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia

NCT01382147 is registered in ClinicalTrials.gov with Prof. Dr. Wolfgang Hiddemann as lead sponsor.

NCT NCT01382147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01382147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia
Lead sponsor
Prof. Dr. Wolfgang Hiddemann
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2009
Completion date
July 5, 2017
Enrollment
396 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia